Posted by Michael Wonder on 21 Sep 2016
DBV Technologies receives FDA fast track designation for Viaskin Milk for the treatment of cow’s milk protein allergy
21 September 2016 - DBV first to announce fast track designation for IgE-mediated CMPA; Viaskin Milk is currently being investigated in a Phase IIb trial.
DBV Technologies today announced that the U.S. FDA has granted fast track designation for Viaskin Milk, the Company’s investigational treatment for paediatric patients two years of age and older with Immunoglobulin E (IgE)-mediated cow’s milk protein allergy (CMPA).
There are currently no approved treatments for CMPA, the most common food allergy in infants and young children.
